Niagen Bioscience Inc logo

Niagen Bioscience Inc

NAGE | NASDAQ
Chart Builder DCF Calculator
$3.04
+$0.05 (+1.67%)
At close: Sep 21, 2026, 4:00 PM ET
$3.09
+$0.05 (+1.63%)
Pre-market: Sep 22, 2026, 7:04 AM ET

Company Profile

Niagen Bioscience, Inc. operates as a bioscience company engages in developing healthy aging products. The company operates through Consumer products; Ingredients; and Pharmaceutical Segments. It provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; nicotinamide adenine dinucleotide (NAD+), an essential coenzyme that regulates cellular metabolism; and develops and commercializes proprietary-based ingredient technologies, including food-grade, Niagen, and pharmaceutical-grade Niagen and supplies these ingredients as raw materials to the manufacturers of consumer products. In addition, it commercializes NAD+ precursor nicotinamide riboside as the flagship ingredient under NIAGEN brand name. The company distributes TRU NIAGEN products direct to consumers through its propriety e-commerce platform TRUNIAGEN.com, Amazon, and other internet marketplaces, as well as specialty retailers and authorized healthcare practitioners resellers. The company was formerly known as ChromaDex Corporation and changed its name to Niagen Bioscience, Inc. in March 2025. Niagen Bioscience, Inc. was founded in 1999 and is headquartered in Los Angeles, California.

Key Executives

Name Position
Robert N. Fried Chief Executive Officer & Director
Michiko Kelley Chief Marketing Officer
Ozan Pamir Chief Financial Officer & Principal Accounting Officer
Andrew Shao Senior Vice President of Global Regulatory & Scientific Affairs
Carlos Lopez Senior Vice President & General Counsel
Chu Yan Managing Director of Asia Pacific
Frank Louis Jaksch Jr. Co-Founder & Chairman
James Lee Controller
Kendall Knysch Head of Media Relations & Partnerships
Wesley Yu Vice President of Finance

Latest SEC Filings

No SEC filings available
View All SEC Filings
Niagen Bioscience Inc
Niagen Bioscience Inc logo
Country United States
IPO Date Jun 23, 2015
Industry Biotechnology
Sector Healthcare
Employees 117
CEO Robert N. Fried

Contact Details

10900 Wilshire Blvd, Suite 600 Los Angeles, California 90024 United States

Stock Details

Ticker Symbol NAGE
Exchange NASDAQ
Fiscal Year n/a
Reporting Currency USD
CIK Code 0001386570
CUSIP Number 171077407
ISIN Number US1710774076
SIC Code n/a

© 2026 bestshares.com. All rights reserved.